CANbridge Pharmaceuticals Inc.
HKEX:1228.HK
Overview | Financials
Company Name | CANbridge Pharmaceuticals Inc. |
Symbol | 1228.HK |
Currency | HKD |
Price | 0.195 |
Market Cap | 82,843,472 |
Dividend Yield | 0% |
52-week-range | 0.187 - 1.27 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. James Qun Xue M.B.A., Ph.D. |
Website | https://www.canbridgepharma.com |
An error occurred while fetching data.
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD